ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1105

PDGFA and TGFB1, Key Genes to Discriminate Autoimmune Diseases-Related Interstitial Lung Disease from Idiopathic Pulmonary Fibrosis?
Abstract Number: 1106

Factors Associated with Relapse in Giant Cell Arteritis Treated with Tocilizumab. Multicenter Open-label Study of 407 Patients
Abstract Number: 1107

Investigating Pyrexia of Unknown Origin: A Rheumatologist’s Perspective
Abstract Number: 1108

The Needed Daily Dose of Colchicine in Patients with Familial Mediterranean Fever May Be Higher in Women, a Study on Behalf of the JIR Cohort
Abstract Number: 1109

Differences Between Correlation and Causal Inference in Detecting Predictors of Undefined Crystal Arthropathy in Women
Abstract Number: 1110

Microvascular Abnormalities in COVID-19 Survivors and LONG COVID
Abstract Number: 1111

Impact of Scleroderma, Antiphospholipid Syndrome, Behçet’s Disease, and Dermatomyositis on Mortality Among Hospitalized Patients with Pulmonary Embolism
Abstract Number: 1112

Pleuroparenchymal Fibroelastosis Associated with Connective Tissue Diseases (PPFE-CTD)
Abstract Number: 1113

2nd Analysis of IgG4-Related Disease in a Diverse Long Island Population: Utilizing Serological and Histological Markers for Assessing Treatment Response
Abstract Number: 1114

Nintedanib in Autoimmune Disease-related Interstitial Lung Disease: Real-life Effectiveness, Safety and Tolerance in a Spanish Multicenter Study
Abstract Number: 1115

Rheumatic Disease Patients: Assessment of Hydroxychloroquine’s Effects on QTc Intervals with Weight Based Dosing (RAISE-QT) Study
Abstract Number: 1116

Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry
Abstract Number: 1117

JAK Inhibitor Therapy in Refractory Uveitis Due to Immune-mediated Inflammatory Disorders. Multicenter Study and Literature Review
Abstract Number: 1118

The Performance of Behcet’s Disease Clinical Diagnostic Criteria in a Low Prevalence Region. A Retrospective Single Center Cohort Study
Abstract Number: 1119

Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].